Neuropathic Pain Components in Patients with Lumbar Spinal Stenosis

Si Young Park, Howard S An, Seong Hwan Moon, Hwan Mo Lee, Seung Woo Suh, Ding Chen, and Jin Ho Jeon

1Department of Orthopedic Surgery, Korea University College of Medicine, Seoul, Korea; 2Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA; 3Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea; 4Department of Orthopedic Surgery, The Second Hospital of Xiangya, Central South University, Changsha, Hunan, P.R. China.

Received: May 7, 2014
Revised: August 20, 2014
Accepted: September 1, 2014
Corresponding author: Dr. Si Young Park, Department of Orthopedic Surgery, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea. Tel: 82-2-920-6605, Fax: 82-2-924-2471 E-mail: drspine90@gmail.com

The authors have no financial conflicts of interest.

Purpose: To determine the prevalence and characteristics of neuropathic pain (NP) in patients with lumbar spinal stenosis (LSS) according to subgroup analysis of symptoms. Materials and Methods: We prospectively enrolled subjects with LSS (n=86) who were scheduled to undergo spinal surgery. The patients were divided into two groups according to a chief complaint of radicular pain or neurogenic claudication. We measured patient’s pain score using the visual analog scale (VAS), Oswestry Disability Index (ODI) and Leads Assessment of Neuropathic Symptoms and Signs (LANSS). According to LANSS value, the prevalence of NP component pain in patients with LSS was assessed. Statistical analysis was performed to find the relationship between LANSS scores and the other scores. Results: From our sample of 86 patients, 31 (36.0%) had a NP component, with 24 (63.4%) in the radicular pain group having NP. However, only seven patients (15.6%) in the neurogenic claudication group had NP. The LANSS pain score was not significantly correlated with VAS scores for back pain, but did correlate with VAS scores for leg pain (R=0.73, p<0.001) and with ODI back pain scores (R=0.54, p<0.01). Conclusion: One-third of the patients with LSS had a NP component. The presence of radicular pain correlated strongly with NP. The severity of leg pain and ODI score were also closely related to a NP component. This data may prove useful to understanding the pain characteristics of LSS and in better designing clinical trials for NP treatment in patients with LSS.

Key Words: Neuropathic pain, spinal stenosis, visual analog scale, Oswestry Disability Index, Leads Assessment of Neuropathic Symptoms and Signs

INTRODUCTION

The etiology of chronic pain disorders is heterogeneous, comprising nociceptive, neuropathic, and mixed pain pathways. Neuropathic pain (NP) has been defined as pain initiated or caused by a primary lesion or dysfunction of the nervous system1 and which may arise as a consequence of a lesion or disease affecting the somato-
sensory system. Diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and post-spinal cord injury pain are classic examples of NP. It is believed that NP serves an important role in the pathogenesis of many diseases related to the spine. However, the diagnosis of NP remains clinical and is based on a characteristic symptom profile and diagnostic tests.

Low back pain (LBP) is one of the most challenging chronic pain disorders to treat. Chronic LBP can involve both the back and the legs. In addition, both neuropathic and nociceptive pain pathways contribute to lower back and associated leg pain. Generally, the leg pain component is due to NP, and the back pain component is due to nociceptive mechanisms. Moreover, about 20% of patients with LBP pain suffer from a NP component. It is important to remember that LBP is not a diagnosis but rather describes a constellation of symptoms. LBP is produced by numerous conditions, resulting in difficulty in understanding and anticipating the clinical course. Due to the heterogeneous pathophysiology of LBP, some clinical pain trials have obtained poorer results than other studies of NP conditions, such as diabetic neuropathy. This highlights a need to better characterize the specific pathophysiology of LBP in order to establish optimal treatment regimens. For example, a medication indicated to treat NP, such as pregabalin, might be considered a first-line drug for patients with lumbar spinal stenosis (LSS) when NP is a significant component of the overall presenting symptom complex.

LSS is a clinical syndrome caused by narrowing of the spinal canal with encroachment on neural structures surrounding bone and soft tissue. Its clinical symptoms vary but appear as a result of neurovascular mechanisms, nerve root excitation, or mechanical compression of the spinal canal. These mechanisms can concur simultaneously. Patients typically present either with LBP and radicular leg pain or with neurogenic claudication. Because lumbar flexion increases the available space in the spinal canal, patients usually complain of clamping pain in the buttocks and legs when walking, which disappears with sitting or lumbar flexion. However, radicular pain, which may not improve with flexion, can also be attributed to spinal stenosis.

Spinal stenosis is the most common reason for lumbar spine surgery in middle-age and elderly populations, likely because of the degenerative pathogenesis. Some studies on the prevalence of NP components in patients with sciatica or radiculopathy have revealed a higher prevalence of NP in patients with severe radiculopathy or neurologic deficits. Attal, et al. found that over 30% of patients with chronic LBP had neuropathic limb pain on the DN4 questionnaire. Moreover, over 70% of patients with neurologic deficits had NP. However, few have studied NP pain components in patients with spinal stenosis. In this study, we aimed to determine the extent of the NP component using the Leads Assessment of Neuropathic Symptoms and Signs (LANSS) scale and to identify the relationships between NP and symptom characteristics in patients with LSS scheduled to undergo surgery.

MATERIALS AND METHODS

Study design and participants
This prospective study was performed between March 2010 and May 2012. Eighty-six consecutive patients with spinal stenosis who were scheduled to undergo spinal surgery were enrolled. All patients had moderate to severe symptoms, such as radicular leg pain and neurogenic claudication, related to LSS. MRI was performed in all patients to obtain confirmatory cross-sectional imaging of the LSS at one or more levels. Exclusion criteria included cauda equina syndrome, spinal infection, tumor, or spinal fracture. Patients with peripheral arterial occlusive diseases, severe diabetic neuropathy, or diabetic foot were also excluded from this study. All patients who agreed to be involved in this study provided written informed consent. The Institutional Review Board of our hospital approved the study. All patients completed self-assessment questionnaires and provided demographic and clinical information, including socio-demographic data and symptoms related to LSS. Patients were characterized as having predominant radicular pain or neurogenic claudication. Patients with radicular pain that did not improve upon flexion were classified into the radicular pain group.

Measures
The intensity of pain in the back and/or legs was measured using a 100-mm visual analog scale (VAS) on which a score of 0 indicates no pain and a score of 100 indicates the worst conceivable pain. Health-related quality of life (HRQoL) was assessed using the Korean version of the Oswestry Disability Index (ODI). The LANSS was used to assess the sensory descriptions of pain provided by the patient and from a bedside examination of sensory dysfunction. Positive scores on the LANSS identified patients with pain that was predom-
inantly neuropathic in origin. The sensitivity and specificity were 85% and 80%, respectively.\textsuperscript{19-21} All patients were assessed using the LANSS pain scale. A score \(<12\) indicated that neuropathic mechanisms were unlikely, whereas a score \(\geq12\) suggested that neuropathic mechanisms were likely (Table 1).\textsuperscript{19} The primary focus of this study was to determine the prevalence of NP components in patients with LSS using the LANSS pain scale. The secondary focus was to explore potential relationships between clinical symptoms and NP.

**Statistical analysis**

All qualitative variables are reported as frequencies and percentages. Quantitative variables are described as means with standard deviation. We divided participants into two groups by their main symptoms. Variables were analyzed using Fisher’s exact test or the Mann-Whitney U test. The relationships between LANSS score and co-morbidities including diabetes mellitus (DM) and hypertension were assessed using logistic regression analysis. The correlations between LANSS score and continuous variables, such as the VAS and ODI scores, were calculated using Spearman’s correlation coefficient. SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. All \(p\)-values\(<0.05\) were accepted as statistically significant.

**Table 1. Leads Assessment of Neuropathic Symptoms and Signs Scale**

| A. Pain questionnaire |  |
|-----------------------|--|
| 1) Does your pain feel like strange, unpleasant sensations in your skin? Words like pricking, tingling, pins and needles might describe these sensations. |  |
| No: my pain doesn’t really feel like this (0) |  |
| Yes: I get these sensations quite a lot (5) |  |
| 2) Does your pain make the skin in the painful area look different from normal? Words like mottled or looking more red or pink might describe the appearance. |  |
| No: my pain doesn’t affect the color of my skin (0) |  |
| Yes: I’ve noticed that the pain does make my skin look different (5) |  |
| 3) Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant sensations when lightly stroking the skin, or getting pain when wearing tight clothes might describe the abnormal sensitivity. |  |
| No: my pain doesn’t make my skin abnormally sensitive in that area (0) |  |
| Yes: my skin seems abnormally sensitive to touch in that area (3) |  |
| 4) Does your pain come on suddenly and in bursts for no apparent reason when you’re still? Words like electric shocks, jumping and bursting describe these sensations. |  |
| No: my pain doesn’t really feel like this (0) |  |
| Yes: I get these sensations quite a lot (2) |  |
| 5) Does your pain feel as if the skin temperature in the painful area has changed abnormally? Words like hot and bursting describe these sensations. |  |
| No: I don’t really get these sensations (0) |  |
| Yes: I get these sensations quite a lot (1) |  |

| B. Sensory test |  |
|----------------|--|
| 1) Alldynia |  |
| Examine the response to lightly stroking cotton wool across the non-painful area and then the painful area. If normal sensations are experienced in the non-painful site, but pain or unpleasant sensations (tingling, nausea) are experienced in the painful area when stroking, alldynia is present. |  |
| No: normal sensation in both area (0) |  |
| Yes: alldynia in painful area only (5) |  |
| 2) Altered pin-prick threshold (PPT) |  |
| Determine the pin-prick threshold by comparing the response to 23 gauge (blue) needle mounted inside a 2 mL syringe barrel paced gently on to skin in a non-painful and then painful areas. If a sharp pin prick is felt in the non-painful area, but a different sensation is experienced in the painful area e.g. none/blunt only (raised PPT) or a very painful sensation (lowered PPT), an altered PPT is present. If a pinprick is not felt in either area, mount the syringe onto the needle to increase the weight and repeat. |  |
| No: equal sensation in both areas (0) |  |
| Yes: altered PPT in painful area (3) |  |

Scoring: add values in parentheses for sensory description and examination findings to obtain overall score. Total score (maximum 24). If score\(<12\), neuropathic mechanisms are unlikely to be contribution to the patient’s pain. If score\(\geq12\), neuropathic mechanisms are likely to be contributing to the patient’s pain.
Eighty-six patients (34 men, 52 women; mean age: 66.3±5.9) were included in this study. All patients were diagnosed with LSS using MRI during the preoperative period. The most frequently involved level was L4–5. The mean duration of symptoms was 9 months. The mean intensities of back and leg pain were 4.6±2.3 and 6.2±3.1, respectively. The mean ODI score was 23.4±12.7. The mean LANSS score was 7.2±5.6 (range: 0–24). When organizing patients according to LANSS guidelines,31 31 patients (36.0%) had NP as indicated by scores ≥12 (Table 2).

Seventy-eight percent of patients had both radicular pain and NC. All patients indicated either a predominance of radicular pain over NC or vice versa. There were 41 patients with predominant radicular pain and 45 patients with predominant neurogenic claudication; there were no significant differences in sex, age, BMI, or co-morbidities between these two groups. Forty-one patients were classified as having primary radicular pain symptoms or predominant radicular pain. Grouping primary and predominant NC together, there were 45 patients with neurogenic claudication. VAS scores on the leg were significantly higher in the radicular pain group, while VAS scores for the back were not significantly different between the two groups. Twenty-four patients (63.4%) in the radicular pain group had NP, while only seven patients (15.6%) in the neurogenic claudication group had NP (p<0.05) (Table 3, Fig. 1).

A significant correlation was observed between LANSS and VAS scores for leg pain (R=0.73, p<0.001) and between LANSS and ODI scores (R=0.54, p<0.01). VAS scores for back pain, age, sex, duration of symptoms, and level of involvement did not correlate significantly with LANSS score (Table 4). Also, co-morbidities, including DM or hypertension, were not significantly related with LANSS scores (Table 5).

DISCUSSION

Lumbar spinal stenosis causes a range of clinical symptoms, including back pain, radicular pain, neurogenic claudication, and neurologic deficits.22 The heterogeneity of the clinical symptoms and pathophysiology of LSS contributes to the difficulty in understanding the actual source of pain. Attal, et al.14 demonstrated a higher prevalence of NP components in patients with chronic LBP. However, that study did not differentiate between the causes of the chronic LBP. In this

| Table 2. Demographic Data |
|---------------------------|
| **Number of patients**    | 86 |
| **Sex (M/F)**             | 34/52 |
| **Age (yr-old)**          | 66.3±5.9* |
| **Co-morbidity (%)**      |   |
| Hypertension              | 61 (70.9) |
| Diabetes mellitus (type II)| 49 (56.7) |
| **Level (%)**             |   |
| L2–3                      | 5 (5) |
| L3–4                      | 9 (10) |
| L4–5                      | 39 (45) |
| L5–S1                     | 17 (20) |
| Multiple levels           | 26 (30) |
| **Symptoms (%)**          |   |
| Radicular pain alone      | 8 (9) |
| Neurogenic claudication alone | 11 (13) |
| Combined                  | 67 (78) |
| **Pain scores**           |   |
| VAS back (0–10)           | 4.23±1.35* |
| VAS leg (0–10)            | 5.93±1.64* |
| ODI (0–45)                | 24.76±5.74* |
| LANSS (0–25)              | 8.26±5.36* |
| Over 12 (%)               | 31 (36) |
| Less than 12 (%)          | 55 (64) |

LANSS, Leads Assessment of Neuropathic Symptoms and Signs; ODI, Oswestry Disability Index; VAS, visual analog scale. *Mean±standard deviation.
study, we found a higher prevalence (36%) of NP components in patients with LSS than that reported in other studies of patients with LBP. In subgroup analysis, patients in the radicular pain group had higher LANSS scores than patients in the claudication group. Almost two-thirds of patients in the radicular pain group had LANSS scores over 12, indicating NP; meanwhile, only seven patients (15.6%) in the claudication group had LANSS scores consistent with NP.

Several screening tools have been introduced to identify NP. The LANSS pain scale was the first tool to be developed and contains five symptom items and two clinical examination items. The LANSS pain scale can distinguish patients with NP from those with nociceptive pain with high reliability and validity. Adequate psychometric evidence has also been demonstrated for the measurement of treatment effects.

In the present study, a NP component was correlated with leg pain but not back pain. Moreover, radicular pain in patients with LSS seemed to be mainly related to a NP component. Compared to patients in the neurogenic claudication group, more severe leg pain was demonstrated in patients in the radiculopathy group. Kovacs, et al. reviewed and reported that patients with radicular pain show poorer outcomes, despite being amenable to surgery. This might be due to the radicular symptoms belonging more to the NP group, with its sensitization of peripheral nerves or the central nervous system, than to the nociceptive pain group. This may represent a mechanism in patients with radicular pain that is more difficult to treat.

LSS can present in several ways but often presents as neurogenic claudication or radicular pain. Neurogenic claudication in patients with LSS is characterized by bilateral or unilateral thigh or calf pain or weakness when walking. It is thought that narrowing of the spinal canal results from degenerative changes of the spine, leading to compression or ischemia of the lumbar sacral nerve roots. In contrast, radicular pain (e.g., sciatica) is thought to be due to nerve root irritation from chemical or mechanical inflammation or from direct neural compression in the central canal. Lumbar flexion does not improve radiculopathy, and the symptoms do not always occur independently but rather can be mixed. In our study, patients with LSS also complained of radicular pain and/or neurogenic claudication; however, NP appeared to be more related to radicular pain and not neurogenic claudication. A higher VAS score for leg pain was closely related to higher LANSS score. On correlation analysis, ODI score was also correlated with LANSS score, suggesting that NP results in more leg than back pain and can significantly worsen functional status. As reported by Freynhagen, et al., leg symptoms are the result of NP, but back pain is not. However, in regard to leg symptoms, radiculopathy was more strongly related to a NP component. Our study suggests that degenerative spinal disorders such as LSS, which produce back and leg pain, have both

---

**Table 4.** Correlation between Pain or Functional Scores and LANSS Scores in Patients with Lumbar Spinal Stenosis (Spearman’s Correlation Test)

|                      | R     | p value |
|----------------------|-------|---------|
| VAS back pain        | -0.133| 0.26    |
| VAS leg pain         | 0.728 | <0.001  |
| Duration of symptoms | 0.183 | 0.41    |
| ODI                  | 0.544 | <0.001  |
| Sex                  | 0.212 | 0.26    |
| Age                  | -0.097| 0.37    |

LANSS, Leads Assessment of Neuropathic Symptoms and Signs; ODI, Oswestry Disability Index; VAS, visual analog scale. p<0.05 is statistically significant.

**Table 5.** Correlation between Co-Morbidities and LANSS Scores in Patients with Lumbar Spinal Stenosis

|                      | LANSS                  | p value |
|----------------------|------------------------|---------|
| DM type II           | 0.544 (0.131–2.266)    | 0.341   |
| Hypertension         | 0.261 (0.021–0.539)    | 0.129   |

DM, diabetes mellitus; LANSS, Leads Assessment of Neuropathic Symptoms and Signs. Multivariate Logistic regression analysis: all tested variables adjusting for age, sex, and BMI.
neuropathic and nociceptive pain components.

Several diseases, such as DM, hypertension, or hyperlipidemia, might involve NP components. LSS typically presents in aged populations, amongst whom DM and hypertension are very common. In our study population, 70% of participants had hypertension and 56% had DM. Attal, et al. showed that, among patients with chronic LBP, over 30% have neuropathic limb pain. However, this study did not rule out the effects of DM or hypertension. In contrast, in this study, we excluded patients with severe diabetic neuropathy or peripheral arterial occlusive disease. We also confirmed co-morbidities in patients before surgery and found no differences between the two groups. Given that we excluded the effects of other comorbidities, this study should be more accurate than other studies, perhaps resulting in the much higher percentage of NP in LSS patients.

The treatment of NP is still a challenge. The first step is treatment of the underlying pathology, but the importance of pharmacologic treatment of the NP component is increasing. Various types of drugs, including antidepressants such as selective serotonin norepinephrine reuptake inhibitors (SSNRI), calcium channel α2-δ ligands, opioid analgesics, and topical lidocaine, have all been recommended. These drug classes might also be helpful in patients with LSS, especially in cases of severe radiculopathy, since a NP component seems to play an important role in leg pain and the severity of pain. In some randomized clinical trials of patients with spinal stenosis, different results were obtained between patients with neurogenic claudication and patients with radicular pain. Better results from surgery were expected in patients with neurogenic claudication and patients with radiologic pain. In summary, one-third of patients with LSS had a NP component. Radicular pain correlated more strongly with NP than neurogenic claudication. The severity of leg pain and ODI score also demonstrated strong relationships with a NP component. These results will be useful to understanding the characteristics of pain in LSS and in designing future clinical drug trials.

ACKNOWLEDGEMENTS

This work was supported by Korea University Research Fund (K1132311).

REFERENCES

1. Merskey H, Bogduk H. Classification of Chronic Pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle (DC): IASP Press; 1994.
2. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7.
3. Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine (Phila Pa 1976) 1987;12:264-8.
4. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185-90.
5. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
6. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurminen T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
7. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-88.
8. Hall S, Bartleson JD, Onofrio BM, Baker HL Jr, Okazaki H, O’Duffy JD. Lumbar spinal stenosis. Clinical features, diagnostic procedures, and results of surgical treatment in 68 patients. Ann Intern Med 1985;103:271-5.
9. Epstein NE, Maldonado VC, Cusick JF. Symptomatic lumbar spinal stenosis. Surg Neurol 1998;50:3-10.
10. Kovacs FM, Urrutia G, Alarécon JD. Surgery versus conservative treatment for symptomatic lumbar spinal stenosis: a systematic review of randomized controlled trials. Spine (Phila Pa 1976) 2011; 36:E1335-51.
11. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery for degenerative conditions. Spine (Phila Pa 1976) 2005;30:1441-5.
12. Weinstein JN, Tosteson TD, Livadie JD, Tosteson AN, Blood E, Hanscom B, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med 2008;358:794-810.
13. Rados I, Sakic Zdravevic K, Hrgovic Z. painDETECT questionnaire and lumbar epidural steroid injection for chronic radiculopa-
27. Kobayashi S, Baba H, Uchida K, Kokubo Y, Kubota C, Yamada S, et al. Effect of mechanical compression on the lumbar nerve root: localization and changes of intraradicular inflammatory cytokines, nitric oxide, and cyclooxygenase. Spine (Phila Pa 1976) 2005;30:1699-705.

28. Kobayashi S, Kokubo Y, Uchida K, Yayama T, Takeno K, Negoro K, et al. Effect of lumbar nerve root compression on primary sensory neurons and their central branches: changes in the nociceptive neuropeptides substance P and somatostatin. Spine (Phila Pa 1976) 2005;30:276-82.

29. Freynhagen R, Baron R, Tölle TR, Stemmler E, Gockel U, Stevens M, et al. Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr Med Res Opin 2006;22:529-37.

30. Merskey H. Clarifying definition of neuropathic pain. Pain 2002;96:408-9.

31. Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009;9:71-8.

32. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.

33.葛森 S, 芳川 H, 藤原 K, 内村 T, 玉野 K, 他 et al. 神経圧迫下でのラジキュラ神経の局所および変化に対する局部抗炎症性サイトカイン、nitric oxide、およびcyclooxygenaseの影響。Spine (Phila Pa 1976) 2005;30:1699-705.